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Abstract
Underdiagnosis of Clostridium difficile infection (CDI) because of lack of clinical suspicion or the use of non-sensitive diagnostic tech-
niques is a known problem whose real magnitude has not yet been quantified. In order to estimate the extent of this underdiagnosis,
we performed C. difficile cultures on all unformed stool specimens sent—irrespective of the type of request—to a series of laboratories
in Spain on a single day. The specimens were cultured, and isolates were characterized at a central reference laboratory. A total of 807
specimens from 730 patients aged ‡2 years were selected from 118 laboratories covering 75.4% of the Spanish population. The esti-
mated rate of hospital-acquired CDI was 2.4 episodes per 1000 admissions or 3.8 episodes per 10 000 patient-days. Only half of the
episodes occurred in patients hospitalized for >2 days. Two of every three episodes went undiagnosed or were misdiagnosed, owing to
non-sensitive diagnostic tests (19.0%) or lack of clinical suspicion and request (47.6%; mostly young people or non-hospitalized patients).
The main ribotypes were 014/020 (20.5%), 001 (18.2%), and 126/078 (18.2%). No ribotype 027 strains were detected. Strains were fully
susceptible to metronidazole and vancomycin. CDI was underdiagnosed in diarrhoeic stools in a high proportion of episodes, owing to
the use of non-sensitive techniques or lack of clinical suspicion, particularly in people aged <65 years or patients with community-
acquired diarrhoea. C. difficile toxins should be routinely sought in unformed stools of any origin sent for microbiological diagnosis. The
ribotype 027 clone has not yet disseminated in Spain.
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Introduction
Clostridium difficile infection (CDI) is a disease in which clinical
symptoms range from mild diarrhoea to toxic megacolon. CDI is
suspected mainly in hospitalized patients with a previous history of
antimicrobial therapy, although community-acquired disease and
cases in antimicrobial-naı¨ve patients are increasingly being
described [1]. The worldwide increase in the incidence of CDI and
the emergence of the hypervirulent ribotype 027 (NAP1 and REA
type BI) strain of C. difficile have led many countries to determine
the incidence of CDI in order to establish the burden of this dis-
ease. Clinicians often fail to suspect CDI in patients with diarrhoea,
and many microbiology laboratories apply suboptimal diagnostic
techniques [2]. However, the number of missed episodes of CDI
has not been evaluated in a large nationwide study estimating the
role of clinicians andmicrobiologists in underdiagnosis.
In order to estimate the extent of and reasons for under-
diagnosis of CDI, we performed C. difficile cultures on all
unformed stool specimens (irrespective of the clinician’s
request) sent to a large group of microbiology laboratories
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in Spain on a single day. We compared the reference labora-
tory results with those of the participating laboratories.
Toxigenic strains were phenotyped and genotyped.
Materials and Methods
Study design
We invited 122 Spanish microbiology laboratories to select
and send to a central reference laboratory all unformed
stool specimens received on a single day, regardless of
patient age/origin (inpatients and outpatients), the diagnosis
requested by the clinician, or the transport medium (except
when this contained sporicides, e.g. formaldehyde).
Reference laboratory
The reference laboratory belongs to a 1550-bed tertiary cen-
tre serving a population of c. 715 000 inhabitants.
Stool specimen collection
Approximately 1 mL of selected specimens was added to a
numbered sterile vial and refrigerated at 4C until collection
by a courier service. Specimens were refrigerated before
being collected and transported at 4C to the reference lab-
oratory by the courier service.
Information requested
Each participating laboratory was asked to complete two
types of questionnaire. The first requested information about
the features of the hospital, and the methods and protocols
used for the diagnosis of C. difficile at the time of the study.
Data included the following: population attended, number of
beds (in total and occupied on the day of the study), number
of admissions on the day of the study, and number of stool
specimens processed for any microbiological diagnosis on
the day of the study (indicating the transport media used and
the microbiological diagnosis). If CDI was performed, the
place where diagnosis was made, and, in the case of in-house
CDI testing, the methodology used for the diagnosis were
requested. The second type of questionnaire requested data
on individual stool specimens, including information on the
patient (age, sex, and, when hospitalized, admission date and
ward) and on the specimen (transport medium, analysis
requested by the clinician, and microbiological results
obtained with routine laboratory methods).
Stool specimen processing at the reference laboratory
Because of the uncertain role of toxigenic C. difficile in the
pathogenesis of CDI in children aged <2 years, stool speci-
mens received from the participating laboratories and
obtained from this age group were excluded from the study.
Accepted specimens were numbered sequentially and cul-
tured. About 500 lL of specimen was mixed with 500 lL of
ethanol for 30 min, and the mixture was added to Brazier’s
Clostridium difficile selective agar (Oxoid, Basingstoke, UK)
and incubated anaerobically at 35–37C for 48 h.
Isolation of C. difficile and detection of toxigenic isolates
After incubation, cultures were read, and each different mor-
photype of suspected colonies of C. difficile was isolated and
identified with biochemical tests. Toxin B was detected by
suspending a few colonies in brain–heart infusion broth, incu-
bating for 24 h in an anaerobic atmosphere, and filtering.
The suspension was then tested with the cytotoxicity assay,
which involved adding 500 lL of the filtrate to each of two
shell vials containing a monolayer of human MRC-5 fibro-
blasts. One of the shell vials was used as a control by adding
a neutralizing high-titre C. difficile antitoxin (TechLab, Blacks-
burg, VA, USA). A result was considered to be positive
when a cytopathic effect was observed only in the shell vial
without antitoxin. A test result was not considered to be
negative until after 48 h of incubation at 37C [3].
For the purposes of this study, all patients with toxin-posi-
tive unformed stool specimens were considered to have
CDI.
Gene detection in isolates
Toxinotyping was performed as previously described [4]. Iso-
lates were characterized by PCR-based ribotyping [5]. Phylo-
genetic analysis of ribotyping profiles was conducted with
the unweighted pair group method with arithmetic mean and
Dice coefficients (Bionumerics software 5.0). We considered
two isolates as a cluster when they had ‡99% similarity. Rib-
otypes were named according to the international designa-
tion. When there was no correspondence with international
ribotypes, the letter R followed by a number was used. The
tcdC gene was amplified for only one representative isolate
of clustered strains by PCR, with the method described by
Spigaglia and Mastrantonio [6]. It was then sequenced with
the Big Dye Terminator kit and detected in an AbiP-
rism 3100 automatic DNA sequencer (Applied Biosystems,
Carlsbad, CA, USA). Sequences were aligned with BioEdit
software (http://www.mbio.ncsu.edu/bioedit/bioedit.html).
The tcdA gene (toxin A), tcdB gene (toxin B) and binary-toxin
genes cdtA and cdtB were detected with multiplex PCR [7].
Antimicrobial susceptibility testing
All toxigenic isolates of C. difficile were tested for susceptibil-
ity to metronidazole, vancomycin, teicoplanin, daptomycin,
doxycycline, tigecycline, linezolid, clindamycin, erythromycin,
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ciprofloxacin, levofloxacin, ofloxacin, gatifloxacin, moxifloxa-
cin, rifampicin, meropenem and ertapenem with the Etest
(AB Biodisk, Solna, Sweden) on sheep blood agar with 1 lg
of vitamin K1 and 5 lg of haemin (Oxoid). The MICs were
recorded for each isolate at 48 h. The breakpoints for anti-
microbials were those established by the CLSI [8] or, when
there was no information, based on CLSI recommendations
for aerobic bacteria and other sources.
Data analysis
Data were entered into Microsoft Access 2000, and
SPSS 16.0 software was used for the statistical analysis. Mean
and median values obtained for each hospital size were com-
pared by use of the t-test and the Mann–Whitney U-test
(two-tailed), respectively. Pooled mean rates and proportions
obtained for each hospital size were compared by use of the
Fisher exact test (two-tailed). A p-value of <0.017 was con-
sidered to be statistically significant (three comparisons, Bon-
ferroni correction).
Results
Participating laboratories
We invited 122 laboratories to participate in the study, and
118 (96.7%) accepted. The participating laboratories
belonged to 63 hospitals with <500 beds (small hospitals)
(53.4%), 43 hospitals with 500–1000 beds (medium-sized
hospitals) (36.4%), and 12 hospitals with >1000 beds (large
hospitals) (10.2%). The hospitals were homogeneously dis-
tributed throughout Spain, and had an overall catchment
population of 34 032 876 inhabitants aged ‡2 years (75.4%
of the Spanish population aged ‡2 years at the time) and
62 697 beds. On the day of the study, there were 8478
admissions from patients aged ‡2 years and 52 134 occupied
beds by patients aged >2 years..
Specimens selected for the study
A total of 988 unformed stool specimens from 897 patients
were selected for the study. After reception in the reference
laboratory, 181 specimens belonging to children aged
<2 years were excluded, leaving a final study sample of 807
specimens from 730 patients (from now on, we will refer to
these specimens). The features of specimens and patients are
shown in Table 1.
Identification of toxigenic C. difficile at the reference labora-
tory
In the reference laboratory, C. difficile was cultured in 63 of
the 807 (7.8%) specimens selected for the study. Moreover,
the cytotoxicity assay detected toxigenic isolates in 45 speci-
mens (positive specimens) (positivity rate, 5.6%) from 42
TABLE 1. Features of the 807 stool specimens included in the study
Hospital size
Overall (n = 118)Small (n = 63) Medium (n = 43) Large (n = 12)
Number of stool specimens 264 439 104 807
Proportion of stool specimens (%) that were processed for CDI in the participating laboratories and recovered from:
All patientsa 20.1 24.4 24.0 22.9
Patients included in the following age groupsb:
Children (2–16 years) 6.0 3.6 0 3.7
Median age group (16–65 years) 11.2 22.9 24.4 19.0
Elderly (>65 years) 41.1 41.7 58.3 43.0
Patients with the following originsa:
Non-hospitalized or hospitalized for <3 days 9.8 11.8 13.7 11.3
Hospitalized for ‡3 days 63.5 53.7 48.6 55.2
Number of patients from whom stool specimens were selected 235 399 96 730
Proportion of males (%)a 50.0 52.1 44.8 50.5
Median age (years) of patients (IQR)c 49.8 (23.9–71.0) 51.3 (24.6–73.4) 39.9 (7.4–63.5) 49.9 (23.5–71.5)
Main origin of patients (%)c:
Emergency department 40.0 38.1 34.9 38.3
General medicine 18.7 15.0 10.5 15.7
Gastrointestinal medicine 10.4 11.4 10.5 11.0
Paediatrics 9.1 10.1 14.0 10.3
Haematology and oncology 5.2 5.7 10.5 6.1
Nephrology 1.7 1.8 5.8 2.4
Other 14.9 17.9 13.8 16.2
Proportion of patients who were hospitalized for ‡3 days (%)d 22.4 31.5 37.0 29.2
CDI, Clostridium difficile infection; IQR, interquartile range.
aThere were no statistically significant differences between proportions for the three hospital sizes.
bThere were statistically significant differences between proportions in the median age group (16–65 years) for small and medium hospitals (p 0.009). The remaining differ-
ences were not statistically significant.
cThere were statistically significant differences between median age for medium and large hospitals (p 0.016). The remaining differences were not statistically significant.
dThere were statistically significant differences between proportions for small and medium hospitals (p 0.004) and between small and large hospitals (p 0.001). The remaining
differences were not statistically significant.
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patients. The estimated rate of hospital-acquired CDI in Spain
on the day of the study, based on episodes of CDI for
patients hospitalized for at least 3 days diagnosed in the ref-
erence laboratory, and admissions and occupied hospital beds
for patients aged ‡2 years, was 2.4 cases per 1000 admissions
or 3.8 cases per 10 000 patient-days (Table 2).
Local CDI diagnosis
Comparison of the diagnostic results from the participating
laboratories with those obtained from the reference labora-
tory revealed that two of every three episodes went undiag-
nosed in the participating laboratories, owing to non-
sensitive diagnostic tests (19.0%) or lack of clinical suspicion
(47.6%). This lack of suspicion was greater for infected
patients who were not hospitalized or had been hospitalized
for <3 days, and for patients aged £65 years (Table 3).
Analysis of local laboratory performance showed that
almost 95% of laboratories (111 of 118) tested for toxigenic
C. difficile in-house. The main strategies for diagnosis of CDI
were enzyme immunoassay (EIA) performed directly on
stool specimens (overall, 82.9%; small hospitals, 92.9%; med-
ium-sized hospitals, 79.1%; and large hospitals, 50.0%) and
EIA performed both on stool specimens and on isolates
(overall, 9.9%; small hospitals, 5.4%; medium-sized hospitals,
14.0%; and large hospitals, 16.7%). Only 15.3% of laborato-
ries included toxigenic culture in their diagnostic procedures.
Twenty-nine per cent of laboratories that performed EIAs as
part of the CDI diagnosis used techniques that detected
C. difficile toxin A only.
Typing of the isolates
PCR ribotyping showed that two (4.8%) of 42 CDI episodes
were polyclonal, owing to two different toxigenic C. difficile
clones (014/R2 and 014/R16). In another CDI episode
(caused by a ribotype 001 clone), a non-toxigenic strain
(ribotype R28) was also recovered. Ribotypes 014/020, 001
and 126/078 were the most prevalent. Ribotype 027 was
not found. Approximately 7% of isolates were TcdA-nega-
tive and TcdB-positive, and binary toxin only was found in
20.5% of all the toxigenic C. difficile isolates. Finally, the
most frequent toxinotypes were toxinotypes 0 and V
(Table 4).
Antimicrobial susceptibility
All strains were fully susceptible to metronidazole. The
glycopeptides vancomycin, teicoplanin and daptomycin were
also very active against all isolates. Tigecycline was more
active than doxycycline. All strains were susceptible to lin-
ezolid at <2 mg/mL, except for one isolate (2.3%) with an
MIC of 16 mg/mL. Second-generation fluoroquinolones
(ciprofloxacin, levofloxacin, and ofloxacin) showed no activ-
ity, but gatifloxacin (third generation) and moxifloxacin
(fourth generation) showed better activity, with 38.6% of
isolates showing MICs of >2 mg/mL. Almost 20% of iso-
lates tested were resistant to rifampicin, with an MIC of
>32 mg/mL, and most were included in ribotype 001.
Finally, meropenem was four times more active than er-
tapenem according to the geometric means of both carba-
penems (Table 5).
TABLE 2. Reference laboratory results
Hospital size
Overall (n = 118)Small (n = 63) Medium (n = 43) Large (n = 12)
Number of stool specimens with toxigenic Clostridium
difficile strains (positivity rate, %)a
16 (6.1) 18 (4.1) 11 (10.6) 45 (5.6)
Patients with CDI 14 18 10 42
Proportion of male patients with CDI (%)b 5/14 (35.7) 7/18 (38.9) 4/10 (40.0) 16/42 (38.1)
Median age (years) of patients with CDI (IQR)c 68.9 (46.3–78.8) 47.4 (35.0–70.1) 57.0 (32.7–77.0) 54.3 (37.0–77.5)
Proportion of patients with CDI who were hospitalized
for ‡3 days (%)b
6/14 (42.9) 11/18 (61.1) 3/10 (30.0) 20/42 (47.6)
Median age (years) of patients with CDI who were hospitalized
for ‡3 days (IQR)c
77.8 (66.6–83.0) 53.5 (43.8–81.7) 76.7 (62.7–77.3) 71.2 (48.0–80.6)
Median age (years) of patients with CDI who were not hospitalized
or hospitalized for <3 days (IQR)c
54.4 (35.1–75.1) 36.0 (5.5–50.5) 52.1 (32.0–66.8) 45.1 (29.9–63.1)
Estimated rate of hospital-acquired CDI per 1000 admissionsd,e 2.5 2.5 1.7 2.4
Estimated rate of hospital-acquired CDI per 10 000 patient-daysd,f 4.2 4.3 2.4 3.8
Estimated rate of total CDI per 100 000 persons per yeard,g 42.8 45.9 46.9 45.1
CDI, Clostridium difficile infection; IQR, interquartile range.
aThere were statistically significant differences between proportions for medium and large hospitals (p 0.016). The remaining differences were not statistically significant.
bThere were no statistically significant differences between proportions for the three hospital sizes.
cThere were no statistically significant differences between the median ages for the three hospital sizes.
dThere were no statistically significant differences between rates for the three hospital sizes.
eCalculated as the number of CDI episodes in patients aged ‡2 years and hospitalized for ‡3 days per each 1000 admissions of patients aged ‡2 years on study day.
fCalculated as the number of CDI episodes in patients aged ‡2 years and hospitalized for ‡3 days per each 10 000 occupied beds by patients aged >2 years on study day.
gCalculated as the estimated annual number of total CDI episodes in patients aged ‡2 years or more per each 100 000 inhabitants aged ‡2 years.
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Discussion
Data collected from a large number of hospitals in the Span-
ish public health network showed that CDI was frequently
missed, owing to limited clinical awareness and methodologi-
cal limitations in clinical microbiology laboratories.
Almost half of CDI episodes detected in the reference
laboratory were not accompanied by a request to check for
CDI by the attending clinician. The lack of clinical suspicion
was more often recorded for non-hospitalized patients,
patients hospitalized for <3 days, and inpatients aged
<65 years. One limitation of this study concerns the defini-
tion of CDI. We accepted as CDI episodes those cases in
patients with unformed stool specimens sent to the micro-
biology laboratory to search for enteric pathogens in which
C. difficile toxins were detected. In one of the patients, a
Campylobacter jejuni strain was also isolated, but in the
remaining cases toxigenic C. difficile was the only pathogen
identified. Although our literature search revealed no com-
prehensive attempts to quantify and characterize the clinical
unawareness of CDI in hospitalized and non-hospitalized
patients, some studies have partially investigated this prob-
lem. Wanahita et al. [9] showed that unrecognized CDI in in-
patients was responsible for 58% of episodes of unexplained
leukocytosis in a tertiary hospital. Vaessen et al. (44th ICA-
AC, 2004, Abstract number D-1367) performed a 5-month
study in which they compared the frequency of toxigenic
C. difficile in stool specimens from patients hospitalized for
more than 3 days with and without a physician’s request for
detection of CDI, and found similar values in both groups
(8.5% and 8.0%, respectively). On the other hand, several
studies have shown the significance of CDI in the aetiology
of community gastroenteritis, with incidence rates ranging
from 7.7 to 29.5 episodes per 100 000 individuals. In these
studies, most of the positive specimens were not accompa-
nied by a specific request for CDI testing from general prac-
titioners: Bauer et al. [10] found that general practitioners
only requested testing for CDI in 12 of 32 (37.5%) positive
stool specimens. The development of an educational pro-
gramme to raise awareness of CDI among clinicians seems
pertinent.
TABLE 3. Diagnostic yield of participating laboratories
Hospital size
Overall (n = 118)Small (n = 63) Medium (n = 43) Large (n = 12)
Proportion of specimens with toxigenic Clostridium difficile
that were diagnosed as true positives by the participating
laboratories (%)a
5/16 (31.3) 5/18 (27.8) 4/11 (36.4) 14/45 (31.1)
Proportion of specimens with toxigenic C. difficile that were
diagnosed as false negatives by the participating laboratories (%)a
6/16 (37.5) 2/18 (11.1) 1/11 (9.1) 9/45 (20.0)
Proportion of specimens with toxigenic C. difficile that were not
processed for C. difficile by the participating laboratories (%)a
5/16 (31.3) 11/18 (61.1) 6/11 (54.5) 22/45 (48.9)
Proportion of CDI episodes that were detected by the participating
laboratories (all patients) (%)a
5/14 (35.7) 5/18 (27.8) 4/10 (40.0) 14/42 (33.3)
Proportion of CDI episodes that were not detected by the participating
laboratories owing to false-negative diagnosis (all patients) (%)a
5/14 (35.7) 2/18 (11.1) 1/10 (10.0) 8/42 (19.0)
Proportion of CDI episodes (%) that were not detected by the participating laboratories owing to no processing for C. difficile and recovered from:
All patientsa 4/14 (28.6) 11/18 (61.1) 5/10 (50.0) 20/42 (47.6)
Patients not hospitalized or hospitalized for <3 daysa 4/8 (50.0) 7/7 (100) 4/7 (57.1) 15/22 (68.2)
Patients hospitalized for ‡3 daysa 0/6 (0) 4/11 (36.4) 1/3 (33.3) 5/20 (25.0)
Patients aged £65 yearsa 3/6 (50.0) 9/13 (69.2) 4/6 (66.7) 16/25 (64.0)
Patients aged >65 yearsa 1/8 (12.5) 2/5 (40.0) 1/4 (25.0) 4/17 (23.5)
CDI, Clostridium difficile infection.
aThere were no statistically significant differences between proportions for the three hospital sizes.
TABLE 4. Molecular features of Spanish toxigenic Clostrid-
ium difficile isolates
Patients 42
Number of polyclonal episodes (%) 2 (4.8)
C. difficile clones 44
Ribotype (%)
014/020 9 (20.5)
001 8 (18.2)
126/078 8 (18.2)
R1 3 (6.8)
R2 3 (6.8)
087 2 (4.5)
050 1 (2.3)
106 1 (2.3)
R7 1 (2.3)
R9 1 (2.3)
R12 1 (2.3)
R13 1 (2.3)
R14 1 (2.3)
R15 1 (2.3)
R16 1 (2.3)
R29 1 (2.3)
R37 1 (2.3)
TcdA-negative and TcdB-positive clones (%) 3 (6.8)
Binary toxin (%) 9 (20.5)
Toxinotype (%)
0 28 (63.6)
V 8 (18.2)
VIII 3 (6.8)
I 3 (6.8)
XII 1 (2.3)
XXIV 1 (2.3)
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Almost 20% of CDI episodes were missed in the partici-
pating laboratories, owing to the use of non-sensitive tech-
niques in the microbiology laboratory being used to diagnose
CDI. This proportion tended to be greater in laboratories
from small hospitals (35.7%) than in those from medium-
sized hospitals (11.1%) and large hospitals (10.0%). The dif-
ference can be explained by the more frequent use of EIA
(as opposed to toxigenic culture) as the only diagnostic pro-
cedure in laboratories from small hospitals, because these
techniques have shown poor sensitivity (ranging from 32% to
86%). Globally, only 15.3% of laboratories used culture as
part of their diagnostic strategy. This low culture rate was
similar to that found for the 18 Spanish laboratories in the
European survey and in a Spanish questionnaire-based survey
performed in 2007, and is among the lowest reported
national rates, with the exception of those from the UK and
the Republic of Ireland [11–16]. The use of more sensitive
techniques (e.g. molecular detection of the toxin B gene
alone or in combination with detection of glutamate dehy-
drogenase, or the use of toxigenic culture) could optimize
the diagnostic yield of CDI detection in Spanish hospitals
[17].
Data regarding the nationwide frequency of CDI are
scarce and are generally obtained with various methods. A
comparison of our data with those obtained from the litera-
ture revealed the number of cases per 1000 admissions to
be as follows: ours, 2.4; USA, 1.3 (2005); Belgium, 1.5
(2007–2008); Spain, 1.7 (2007); Germany, 4.7 (2007); and
Canada, 4.7 (2007). The numbers of cases per
10 000 patient-days were as follows: ours, 3.8; Europe, 4.1
(2008); Germany, 6.6 (2007); and Canada, 7.3 (2007) [16,18–
21]. Few national surveys have analysed the correlation
between rate of CDI and hospital size, and the available
results are discordant. Like us, Karlstro¨m et al. found no
association between incidence rate and hospital size; how-
ever, greater CDI incidence rates were found in larger hospi-
tals in the first European survey, the 2007 Spanish survey,
the Canadian survey in 1995, and the national point-preva-
lence study in the USA in 2008 [11,13,15,22]. In our opinion,
there are several possible reasons for the differences in the
estimated CDI incidence by hospital size. One reason could
be the greater diagnostic yield of the larger hospitals, owing
to the use of more sensitive diagnostic tests, as occurred in
our study. Another could be the concurrence of two circum-
stances: the fact that nosocomial CDI is most prevalent in
older patients and in patients with more severe infections;
and the highest prevalence of this group in larger hospitals,
as occurs in the USA. Unfortunately, the design of this study
did not allow us to gather information on the types of
patient in each participating hospital.
The results of the molecular characterization of Spanish
isolates of C. difficile were quite similar to those obtained in
the European survey performed in 2008 [18]. However, rib-
otype 027, which was found in 5% of episodes in the Euro-
pean study, was not recovered in Spain. Despite the spread
of this ribotype in most countries in North America and Eur-
ope during recent years [23,24], this strain has only been
isolated, at the time of the study, in two CDI episodes in
Spain, the first in 2007 in a patient transferred from a hospi-
tal in England to a hospital in Madrid, and the second in a
technician working with the isolate [25]. PCR ribotyping
revealed the polyclonal nature of CDI in nearly 5% of epi-
sodes. In 2005, van den Berg et al. [26] found polyclonality in
8.7% of patients with a first episode of CDI diagnosed with
PCR ribotyping. In 2009, Wroblewski et al. [27] found that
13.0% of their episodes had different populations, using bin-
TABLE 5. In vitro activity of 17 antimicrobials tested against Spanish toxigenic Clostridium difficile isolates
Antimicrobial Range (mg/mL) MIC50 (mg/mL) MIC90 (mg/mL) Geometric mean (mg/mL) Breakpoints (mg/mL)
a % resistance
Metronidazole 0.03–0.25 0.094 0.19 0.1011 >8 0
Vancomycin 0.38–2 0.75 1 0.6795 >2 0
Teicoplanin 0.06–0.38 0.125 0.25 0.1507 >2 0
Daptomycin 0.094–1.5 0.38 0.75 0.3586 >1 2.3
Doxycycline 0.016–8 0.032 3 0.1055 >2 11.4
Tigecycline <0.016–0.125 0.032 0.064 0.0348 >0.5 0
Linezolid 0.25–16 0.75 1 0.7525 >4 2.3
Clindamycin 1 to >256 4 >256 13.1618 >2 38.6
Erythromycin 0.5 to >256 1.5 >256 11.8967 >2 40.9
Ciprofloxacin 12 to >32 >32 >32 60.2527 >2 100
Levofloxacin 1.5 to >32 8 >32 13.9265 >2 79.5
Ofloxacin 8 to >32 >32 >32 56.4218 >2 100
Gatifloxacin 0.75 to >32 1 >32 4.9106 >2 38.6
Moxifloxacin 0.5 to >32 1 >32 4.7456 >2 38.6
Rifampicin <0.002 to >32 <0.002 >32 0.0095 >0.5 18.2
Meropenem 0.19–4 0.5 1 0.5916 >4 0
Ertapenem 1 to >32 2 4 2.0598 >4 2.3
aThe only breakpoints for resistance established by the CLSI for anaerobic bacteria are those of metronidazole, clindamycin, moxifloxacin, meropenem, and ertapenem. The
remaining breakpoints were based on CLSI recommendations for aerobic bacteria and other sources.
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ary toxin gene detection by PCR. Tanner et al. [28] found
different multilocus variable-number tandem-repeat analysis
profiles in five (12.8%) of 39 specimens containing ribo-
type 027 strains.
In vitro susceptibility testing revealed no strains resistant to
metronidazole. Other authors, including our group, have
reported cases of resistance to metronidazole [29–33]. Resis-
tance to metronidazole is heterogeneous, and is lost during
specimen handling. Unfortunately, the methods used in this
multicentre study may have favoured the loss of resistance.
In summary, CDI was highly underdiagnosed in Spanish
hospitals, owing to the use of non-sensitive techniques or
the lack of clinical suspicion, particularly in patients with
community-acquired infection and in patients aged <65 years.
C. difficile toxins should be routinely investigated in unformed
stools of any origin sent for microbiological diagnosis. The
ribotype 027 clone had not yet disseminated in Spain during
the study period.
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Appendix 1
The members of the Spanish Clostridium difficile Study Group
are as follows.
I. Perales Palacios and M. L. Michaus Oquin˜ena: Hospital
Txagorritxu, Vitoria, A´lava. M. Pariente Martı´n and M. D.
Crespo Sa´nchez: Complejo Universitario Hospitalario, Albac-
ete. M. Ruiz Garcı´a, L. A´lvarez Paredes, and G. Royo Garcı´a:
Hospital General Universitario, Elche, Alicante. M. Elı´a: Hos-
pital General, Elda, Alicante. M. Navarro Cots: Hospital del
Servicio Valenciano de la Vega Baja, San Bartolome´, Alicante.
W. Sa´nchez-Yebra Romera, M. Morales Torres, and A. Sicilia
Enrı´quez de Salamanca: Complejo Hospitalario Torreca´rde-
nas, Almerı´a. B. Iglesias Rodrı´guez and P. Prendes Pela´ez:
Hospital San Agustı´n, Avile´s, Asturias. L. Barreiro Hurle´ and
J. F. Orda´s A´lvarez: Hospital Carmen y Severo Ochoa, Can-
gas del Narcea, Asturias. M. D. Miguel Martı´nez: Hospital de
Cabuen˜es, Gijo´n, Asturias. M. J. Santos Rionda: Hospital Uni-
versitario Central de Asturias, Oviedo, Asturias. L. Villa Bajo
and F. Va´zquez Valde´s: Hospital Monte Naranco, Oviedo,
Asturias. P. de la Iglesia Martı´nez: Hospital Comarcal de Jar-
rio-Coan˜a, Jarrio, Asturias. I. Sa´nchez Folgueras: HUCA-Insti-
tuto Nacional de Silicosis, Oviedo, Asturias. R. Sa´nchez
Arroyo and A. Go´mez del Campo: Hospital Nuestra Sen˜ora
de Sonsoles, A´vila. R. M. Sa´nchez Silos and J. Blanco Palenci-
ano: Hospital Universitario Infanta Cristina, Badajoz. M. Faj-
ardo Olivares: Hospital Universitario Perpe´tuo Socorro,
Badajoz. J. Vila Estape´, P. Salvador, and M. T. Jime´nez de
Anta: Hospital Clinic, Barcelona. I. Sanfeliu´ Sala and D. Fonta-
nals Aymerich: Corporacio´ Sanita`ria Parc Taulı´, Sabadell, Bar-
celona. M. D. Estivill Navarrete and M. Morta: Fundacio´n
Althaia-Hospital San Joan de Deu, Manresa, Barcelona. A.
Gene´ Giralt and C. Latorre Otı´n: Hospital Sant Joan de De´u,
Esplugues de Llobregat, Barcelona. J. Niubo´ Bosh and R. Mar-
tı´n-A´lvarez: Ciutat Sanita`ria I Universitaria de Bellvitge-Hospi-
tal Princeps d’Espanya, L’Hospitalet de Llobregat, Barcelona.
M. Lung and M. Salvado´ Costa: Laboratorio de Referencia-
Hospital del Mar, Prat de Llobregat, Barcelona. B. Mirelis
Otero and P. Coll Figa: Hospital de la Santa Creu i Sant Pau,
Barcelona. C. San Jose´ Alemany and A. Vilamala Bastarras:
Hospital Comarcal de L’Alt Penede`s, Vilafranca del Penede`s,
Barcelona. J. L. Dı´az de Tuesta del Arco and R. Cisterna
Ca´ncer: Hospital de Basurto, Bilbao, Bizkaia. F. Calvo Muro:
Hospital de Santa Marina, Bilbao, Bizkaia. L. Elorduy Otazu´a
and I. Corral Carranceja: Hospital San Eloy, Barakaldo, Biz-
kaia. A. P. Martı´nez de la Fuente and M. J. Lo´pez de Goi-
koetxea: Hospital de Galdakao, Galdakao, Bizkaia. A. Blasco
Molla and E. Ojeda Ferna´ndez: Complejo Asistencial General
Yagu¨e, Burgos. C. Gimeno Crespo: Hospital Comarcal Santi-
ago Apostol, Miranda de Ebro, Burgos. R. I´n˜iguez Ovando
and P. Teno Sa´nchez: Complejo Hospitalario de Ca´ceres-
Hospital San Pedro de Alca´ntara, Ca´ceres. M. C. Lozano
Domı´nguez and C. Ferna´ndez Gutie´rrez del A´lamo: Hospital
Universitario Puerta del Mar, Ca´diz. A. Sa´nchez Porto: Hos-
pital del S.A.S. de La Lı´nea de la Concepcio´n, La Lı´nea de la
Concepcio´n, Ca´diz. C. de Miguel Sastre and L. Calbo Torrec-
illas: Hospital del S.A.S. de Jerez de la Frontera, Jerez de la
Frontera, Ca´diz. R. Salesa Gutie´rrez de Rozas and L. Martı´-
nez Martı´nez: Hospital Universitario Marque´s de Valdecilla,
Santander, Cantabria. C. J. Te´llez Castillo and R. Moreno
Mun˜oz: Hospital General de Castello´n, Castello´n. A. Lo´pez
Llopis and S. Pesudo Calatayud: Hospital de La Plana, Villa-
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real, Castello´n. J. Lo´pez Barba: Hospital de la Cruz Roja del
Ingesa, Ceuta. J. Martı´nez Alarco´n, M. Torres Narbona, and
M. D. Romero Aguilera: Hospital General, Ciudad Real. E.
Manrique Gonza´lez and R. Carranza Gonza´lez: Hospital Gen-
eral de La Mancha, Alca´zar de San Juan, Ciudad Real. M.
Causse del Rı´o and M. Casal Roma´n: Hospital Universitario
Reina Sofı´a, Co´rdoba. G. Sesen˜a del Olmo, M. J. Rodrı´guez
Escudero, and M. C. Martı´nez Medina: Hospital General Vir-
gen de la Luz, Cuenca. J. Lie´bana Uren˜a and M. C. Maroto
Vela: Hospital Clı´nico Universitario San Cecilio, Granada. C.
Miranda Casas and J. M. Navarro Mari: Hospital General Vir-
gen de las Nieves, Granada. S. Solı´s del Ban˜o and J. Bisquert
Santiago: Hospital General Universitario, Guadalajara. C. Ub-
arrechea Rojo and J. A. Jime´nez Alfaro: Policlı´nica Gipuzkoa,
San Sebastia´n, Gipuzkoa. M. Goma´riz Dı´az and E. Pe´rez Tral-
lero: San Sebastia´n, Gipuzkoa. J. M. Saavedra Martı´n: Hospital
General Juan Ramo´n Jime´nez, Huelva. M. P. Mairal Claver
and M. Ferrero Ca´ncer: Hospital General San Jorge, Huesca.
A. Mena Ribas, C. De´niz Naranjo, and J. L. Pe´rez Sa´enz: Hos-
pital Son Dureta-Complejo Hospitalario, Palma de Mallorca,
Islas Baleares. J. Sa´nchez Go´mez and A. Hurtado Ferna´ndez:
Hospital Can Misses, Ibiza, Islas Baleares. D. Domı´nguez
Go´mez and J. A. Agulla Budin˜o: CHA Arquitecto Marcide-
Novoa Santos, El Ferrol, La Corun˜a. A. A´lvarez Alba and P.
Castro Romero: Hospital General Juan Cardona, El Ferrol,
La Corun˜a. D. Velasco Ferna´ndez and R. Villanueva Gon-
za´lez: Complejo Hospitalario Universitario Juan Canalejo, La
Corun˜a. M. Ojeda Vargas and A. M. Martı´n Sa´nchez: Hospital
Universitario Insular de Gran Canaria, Las Palmas de Gran
Canaria, Las Palmas. R. Lo´pez Medrano and C. Fuster Foz:
Hospital del Bierzo, Ponferrada, Leo´n. A. Remacha, T. Parras
Padilla, and F. Cacho´n Garcı´a: Hospital de Leo´n, Leo´n. J.
Aramburu Arnuelos and A. Nogues Biau: Hospital Universi-
tari Arnau de Vilanova, Lleida. E. Undabeitia: Complejo Hos-
pitalario San Milla´n-San Pedro, Logron˜o, La Rioja. F. Garcı´a-
Garrote, J. M. Pita Carretero and M. P. Alonso Garcı´a:
Complejo Hospitalario Xeral-Calde, Lugo. M. V. Portu´s
Marco and R. Corte´s: Hospital Central de la Cruz Roja Es-
pan˜ola San Jose´ y Santa Adela, Madrid. A. Garcı´a Blanco and
M. Lo´pez-Brea: Hospital Universitario de la Princesa, Madrid.
L. Alcala´, A. Martı´n, M. Marı´n, M. Sa´nchez-Somolinos, P. Ca-
tala´n, T. Pela´ez, and E. Bouza: Hospital General Universitario
Gregorio Maran˜o´n, Madrid. E. Salto Ferna´ndez and J. J. Rod-
rı´guez Otero: Hospital Universitario Doce de Octubre,
Madrid. M. Baquero Mochales: Hospital Universitario Carlos
III, Madrid. M. I. Morosini Reilly and R. Canto´n Moreno: Hos-
pital Ramo´n y Cajal, Madrid. I. Sa´nchez Romero and D. Da´m-
aso Lo´pez: Hospital Puerta de Hierro, Madrid. E. Amor, C.
Bernaola Lorenzo, and J. J. Picazo: Hospital Clı´nico San Car-
los-Complejo Hospitalario, Madrid. S. Garcı´a Bujalance and
A. Gutie´rrez Alte´s: Hospital de la Paz, Madrid. M. A. de Ur-
meneta Rada: Hospital de Cantoblanco, Madrid. J. A. Cuad-
ros Gonza´lez and M. Beltra´n Dubo´n: Hospital Prı´ncipe de
Asturias, Alcala´ de Henares, Madrid. M. Sa´nchez Concheiro,
A. Gonza´lez Torralba, and J. I. Alo´s: Hospital Universitario
de Getafe, Getafe, Madrid. F. J. Merino Ferna´ndez and I. Wil-
helmi de Cal: Hospital Severo Ochoa, Legane´s, Madrid. A.
Delgado-Iribarren and J. F. Valverde: Fundacio´n Hospital Al-
corco´n, Alcorco´n, Madrid. M. T. Pe´rez Pomata and J. L.
Go´mez Garce´s: Hospital General, Mo´stoles, Madrid. M. J.
Gonza´lez Abad and M. Mene´ndez Rivas: Hospital del Nin˜o
Jesu´s, Madrid. M. A. Izquierdo Ruiz de la Pen˜a and F. Herva´s
Maldonado: Hospital Central de la Defensa Go´mez Ulla,
Madrid. P. Bermu´dez Ruiz and J. A. Porras Ballesteros: Hos-
pital Regional Universitario Carlos Haya, Ma´laga. M. Ortega
Torres and A. Pinedo Sa´nchez: Hospital Clı´nico Universitario
Virgen de la Victoria, Ma´laga. J. C. Navarro Madrid and R.
Tejero Garcı´a: Hospital Comarcal, Melilla. L. del Rı´o Medel
and R. Bla´zquez Garrido: Hospital Morales Meseguer, Murcia.
J. Leiva Leo´n: Clı´nica Universitaria de Navarra, Pamplona,
Navarra. A. M. Navascu´es Ortega and C. Ferna´ndez Jau´regui:
Hospital de Navarra, Pamplona, Navarra. V. Martı´nez de Art-
ola: Hospital Virgen del Camino, Pamplona, Navarra. A. Cid
Lama and G. Esteba´n Merue´ndano: Complejo Hospitalario de
Ourense-Hospital Santa Marı´a Nai, Ourense. M. L. Jaime Mu-
niesa and M. A. Rodrı´guez: Hospital General Rı´o Carrio´n, Pa-
lencia. P. A´lvarez Garcı´a and M. Garcı´a Campello: Complejo
Hospitalario, Pontevedra. G. Gonza´lez Mediero and T. Gon-
za´lez del Blanco: Complejo Hospitalario Xeral-Cies, Vigo,
Pontevedra. J
Sevillano Castan˜o and I. Rodrı´guez: Policlı´nico Vigo S. A.-PO-
VISA, Vigo, Pontevedra. M. I. Garcı´a Garcı´a and J. E. Garcı´a
Sa´nchez: Hospital Universitario de Salamanca-Hospital Clı´nic-
o y Hospital Virgen de la Vega, Salamanca. A. Sierra Lo´pez:
Hospital Universitario de Canarias, La Laguna, Santa Cruz de
Tenerife. M. R. Sa´nchez Flores and O´. Dı´ez Gil: Hospital Uni-
versitario Nuestra Sen˜ora de Candelaria, Santa Cruz de Ten-
erife. P. Carrero Gonza´lez, S. Hernando Real, and S. Garcı´a
Carbajosa: Complejo Hospitalario de Segovia (SACYL), Sego-
via. E. Mun˜oz Nun˜o, A. Pascual Herna´ndez, and E. Perea:
Hospital Universitario Virgen de la Macarena, Sevilla. M. Ruiz
Pe´rez de Pipao´n and J. Aznar Martı´n: Hospital Universitario
Virgen del Rocı´o, Sevilla. A. I. Aller Garcı´a and E. Martı´n
Mazuelos: Hospital Universitario Nuestra Sen˜ora de Valme,
Dos Hermanas, Sevilla. T. Nebreda Mayoral and A. Campos:
Complejo Hospitalario de Soria (Santa Ba´rbara-Virgen del
Miro´n), Soria. J. Tapiol Oliva and J. M. Santamarı´a: Hospital
de Tarragona Joan XXIII, Tarragona. P. Chocarro Escanero
and F. J. Ramos Germa´n: Hospital General Obispo Polanco,
Teruel. P. Zamarro´n Fuertes, E. Heredero Ga´lvez, and S.
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Brea Zubicaray: Hospital Virgen de la Salud, Toledo. P. Ra-
mos Reig: Hospital de la Ribera, Alzira, Valencia. N. Orta
Mira and J. Dı´az Ferna´ndez: Hospital Francesc Borja, Gandı´a,
Valencia. N. Aparisi, J. M. Garcı´a Aguayo, and M. Yago: Hos-
pital General de Requena, Requena, Valencia. S. Giner Alma-
raz: Hospital Doctor Moliner, Serra, Valencia. E. Aznar
Oroval and J. Maiquez Richart: Fundacio´n Instituto Valenci-
ano de Oncologı´a (IVO), Valencia. L. Navarro Pe´rez and C.
Segarra Martı´nez: Hospital Arnau de Vilanova, Valencia. R. M.
Ferreruela Vicente, T. Garcı´a Lozano, and J. Garcı´a de Lo-
mas: Hospital Clı´nico de Valencia, Valencia. P. J. Mengual Bui-
gues and J. L. Herna´ndez Tintorer: Hospital General Ba´sico
de la Defensa, Quart de Poblet, Valencia. D. Gonza´lez Gran-
da and E. Ochoa A´vila: Hospital Lluis Alcanyis, Xa´tiva, Valen-
cia. M. A. Bratos Pe´rez and R. O´rtiz de Lejarazu: Hospital
Clı´nico Universitario de Valladolid, Valladolid. A. Go´mez Ni-
eto and M. L. Arranz Pen˜a: Hospital del Rı´o Hortega, Valla-
dolid. B. Lorenzo Vidal: Hospital Medina del Campo, Medina
del Campo, Valladolid. M. F. Brezmes Valdivieso: Hospital
Virgen de la Concha A´rea 11, Zamora. C. Min˜ana Amada:
Hospital Real y Provincial Nuestra Sen˜ora de Gracia, Zar-
agoza. F. J. Castillo Garcı´a and M. C. Rubio Calvo: Hospital
Clı´nico Universitario Lozano Blesa, Zaragoza. M. Omen˜aca
Tere´s, M. L. Aı´sa Iriarte, and M. J. Revillo Pinilla: Hospital
Universitario Miguel Servet, Zaragoza.
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